The therapeutic potential of cannabinoids for people across all age groups, ailments, and circumstances is enormous. From young children to elderly individuals, both CBD and THC applications have provided both ease and relief for a range of problems such as epileptic seizures, pain relief (physical and mental), and even neuropathic symptoms associated with cancer.
One of the biggest challenges this novel treatment faces is the limitation of the human body to absorb these substances properly. With oral administration in particular, once the remedy enters the aqueous phase of the gastrointestinal system (GI Tract), much of the beneficial molecules are released without providing their therapeutic goals. In addition, the liver transforms a large portion of the molecules into other substances, which are likely inactive or may cause unintended side effects.
The lack of an effective drug delivery system for cannabinoid products has created a clear need for an improved platform to administer this medication for patients’ therapeutic needs properly. Furthermore, the fact that these products have been lauded globally for their benefits despite poor bioavailability has paved the way for scientists and pharmacologists to improve, streamline, and enhance these medicinal products to benefit patients worldwide.
The innovative PNL technology provides a unique solution by reformulating and encapsulating the active cannabinoid ingredients that provide a faster onset time, higher bioavailability, and controlled as well as consistent absorption patterns within the human metabolism. Everyone deserves to feel as healthy and well as they can, PNL technology makes that a reality. Learn more about the benefits of PNL below!
4x increase in Cmax and 2.2x increase in AUC
3x faster reach to effective therapeutic blood concentration
Prof. Domb’s research has generated over 700 scientific publications, been cited in over 40,000 publications, and resulted in several products and companies , including Gliadel, Bioprotect, Canker Cover, OraMiost, and Deximun.
Elixie is an industry innovator of uniquely formulated drug delivery systems, with an emphasis on cannabinoid-based therapies. Elixie collaborates with leading research institutions and pharmaceutical chemistry experts, driving cutting-edge therapy formulations and methods to the market, and enabling inclusive treatment for every age, medical condition, and indication.
Yissum is the Hebrew University of Jerusalem’s Technology Transfer company, serving to bridge extraordinary innovations and commercial industries together. Yissum is an esteemed veteran of applying cutting-edge technologies born from academic research to various sectors to address urgent global challenges. With almost 11,000 registered patents, more than 1,000 licensed technologies, and 176 spin-off companies, Yissum boasts the same reputation for excellence and achievement that the Hebrew University is renowned for on a global scale.
Sourasky Medical Center in Tel Aviv’s main hospital complex and the largest acute care medical facility in Israel serves as an internationally recognized hub for academic research and medical innovation. The Sourasky Clinical Research Center’s commitment to R&D and excellence in a medical research setting is what sets it apart as a leader in primary early-phase clinical trials.
Hadassah Medical Center is Hadassah University’s medical research facility, widely recognized as an international leader in translational and clinical studies across various medical disciplines. Hadassah’s Clinical Trials Center is dedicated to bringing laboratory research and patient together, with clinical trials of drugs in their early stages of development being the focus of its investigation.
Galilee Clinical BioResearch is a multi-national entrepreneurial center that offers a comprehensive development solution through breakthrough drug therapies, medical devices, and food supplements. Galilee CBR’s multi-faceted approach accompanies its clients and products from the preclinical phase through final regulatory approval and oversees the remainder of the process, including commercialization and monitoring.
Seligsohn Gabrieli & Co is an Israel-based law firm with a notable reputation for shaping intellectual property laws for more than 80 years. The firm has extensive experience working at an international scale within the scope of intellectual property and continues to impact and shape IP law, both locally and globally.
The California Israel Chamber of Commerce is a California-based non-profit organization dedicated to mediating business relations between Israel and the state of California. With a focus on technology and innovation, the CICC’s network is over 10,000 strong and comprises a diverse group of companies, executives, investors, entrepreneurs, and service providers. The CICC serves as an international platform for Israeli tech and innovation companies to connect with potential stakeholders and bring new ideas to life.